In vitro and in vivo evaluation of leukoreduced red blood cells after automated separation of whole blood
The Reveos System met FDA's criteria for RBC component in vitro quality and in vivo 24-h recovery after 42-day storage.
Authors
- Laurie J. Sutor
- Frances Compton (ORCID: https://orcid.org/0000-0001-6523-7699)
- Marley E. Shipps
- Rebecca L. Sedjo
- Moritz Stolla (ORCID: https://orcid.org/0000-0002-2866-1674)
- Neeta Rugg (ORCID: https://orcid.org/0000-0001-8330-1105)
- Susanne Marschner (ORCID: https://orcid.org/0000-0002-7862-6201)
- S. Lawrence Bailey
- Peter Lopez (ORCID: https://orcid.org/0000-0002-8587-7148)
- Shawnagay Nestheide
- Daire Byrne
- Elissa J. Flaumenhaft
- José A. Cancelas (ORCID: https://orcid.org/0000-0002-1291-7233)
- Larry J. Dumont (ORCID: https://orcid.org/0000-0002-1715-0748)
- Gina K. Aga
- Christina Gloor
- Alice Chen (ORCID: https://orcid.org/0000-0002-7908-2664)
- Caroline Leite
- Nero Evero
Institutions
- Harvard University (US)
- Bloodworks Northwest (US)
- Carter BloodCare (US)
- Dana-Farber Cancer Institute (US)
- Vitalant (US)
- University of Cincinnati (US)
- Terumo (Germany) (DE)
Publication Details
- Journal
- Transfusion
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1111/trf.18427
- Primary Topic
- Blood transfusion and management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Terumo BCT